Rein Therapeutics, Inc.
RNTX institutional ownership changes in Q2 2026: 17 institutions opened or added positions, 4 trimmed or exited. RNTX (Rein Therapeutics, Inc.) is held by 22 institutional investors as of Q2 2026. Top institutional shareholders: Vanguard Capital Management LLC ($3.5M), Citadel Advisors LLC ($2.5M), Geode Capital Management, LLC ($762,540). Institutions were buying, on balance.
Who's Trading
Latest move
Source dates: Price Nov 6, 2026 · Insiders May 28, 2026 · Activists Aug 14, 2026 · Congress none
Top Holders
| Action | ||||||
|---|---|---|---|---|---|---|
Increased | 3.4M(+238.3%) | $3.5M | 0.0% | -40.19% | 43 | |
New | 2.4M | $2.5M | 0.0% | -35.77% | 36 | |
Increased | 733,139(+112.7%) | $762,540 | 0.0% | -60.99% | 27 | |
Increased | 382,515(+147.6%) | $397,816 | 0.0% | -41.66% | 38 | |
Increased | 379,604(+400.1%) | $394,788 | 0.0% | -40.62% | 26 | |
Increased | 326,204(+376.0%) | $339,253 | 0.0% | -51.49% | 26 | |
New | 250,000 | $260,000 | 0.0% | -35.77% | 32 | |
Increased | 159,720(+149.0%) | $166,109 | 0.0% | -51.19% | 25 | |
New | 79,785 | $82,976 | 0.0% | -35.77% | 33 | |
Increased | 57,410(+5506.4%) | $59,706 | 0.0% | -35.90% | 23 | |
Increased | 50,461(+42.3%) | $52,479 | 0.0% | -42.90% | 28 | |
Increased | 45,760(+39.0%) | $47,590 | 0.0% | -45.56% | 27 | |
Unchanged | 42,440 | $44,138 | 0.0% | -55.98% | 0 | |
New | 30,787 | $32,018 | 0.0% | -35.77% | 30 | |
New | 30,528 | $23,315 | 0.0% | -35.77% | 26 | |
Decreased | 19,000(-22.4%) | $19,760 | 0.0% | -42.37% | 0 | |
New | 14,318 | $14,890 | 0.0% | -35.77% | 28 | |
Unchanged | 12,774 | $13,285 | 0.0% | -48.62% | 0 | |
New | 11,742 | $12,212 | 0.0% | -35.77% | 27 | |
Unchanged | 5,097 | $5,301 | 0.0% | -41.66% | 0 |
Showing 1-20 of 25
| Insider | Trade | Traded |
|---|---|---|
| VON RICKENBACH JOSEF H | Buy $5K | |
| VON RICKENBACH JOSEF H | Buy $24K | |
| VON RICKENBACH JOSEF H | Buy $17K | |
| VON RICKENBACH JOSEF H | Buy $4K | |
| WINDSOR JAMES BRIAN | Buy $25K | |
| Voss Capital, LP | Buy $128K | |
| Voss Capital, LP | Buy $248K | |
| Voss Capital, LP | Buy $127K | |
| Voss Capital, LP | Buy $7K | |
| Voss Capital, LP | Buy $42K |
| Filer | Stake | Filed |
|---|---|---|
| ADAR1 Capital Management, LLC | 5.3% | |
| Lynwood Capital Management Inc. | 5.0% | |
| LYTTON LAURENCE W | 4.9% | |
| Voss Capital, LP | 6.6% | |
| BIOS CAPITAL MANAGEMENT, LP | 10.0% | |
| Lynwood Capital Management Inc. | 6.1% | |
| Funicular Funds, LP | 6.7% | |
| LYTTON LAURENCE W | 5.8% | |
| Voss Value Master Fund, LP | 3.5% | |
| BIOS FUND III, LP | 0.7% |
RNTXRein Therapeutics, Inc.Continue exploring
Other Healthcare stocks held by institutions
UNHUnitedHealth Group Incorporated
LLYEli Lilly and Company
TMOThermo Fisher Scientific Inc
JNJJohnson & Johnson
DHRDanaher Corporation
ISRGIntuitive Surgical, Inc.
MRKMerck & Company, Inc.
ABBVAbbVie Inc.
BSXBoston Scientific Corporation
ABTAbbott LaboratoriesQuestions investors ask about RNTX
Who owns RNTX?
22 institutional investors held RNTX on June 30, 2026, led by Vanguard Capital Management LLC ($3.5M), Citadel Advisors LLC ($2.5M) and Geode Capital Management, LLC ($762,540).
How many hedge funds hold RNTX?
22 institutional investors reported RNTX in their 13F filings for the quarter ended June 30, 2026, $8.8M in all. 2 of them are rated Elite.
Are institutions buying or selling RNTX?
Buying, on balance. In Q2 2026, 17 institutions opened or added to positions in RNTX and 4 institutions trimmed or exited.
Data sourced from four public-disclosure sources: SEC 13F, Form 4, 13D/13G, and House/Senate STOCK Act disclosures. Not financial advice. Full disclaimer